Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cibisatamab + Atezolizumab in mCRC
NCT03866239Phase 1Terminated
- Sponsor
- Roche
- Start
- May 2019
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, open-label trial of cibisatamab in colorectal adenocarcinoma, sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 5 years and Confirmed Objective Response Rate up to 5 years. Started May 2019; status: terminated.
02
Drugs
cibisatamab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT03866239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866239.